DARZALEX FASPRO® dosing schedules for adult patients with newly diagnosed multiple myeloma*
For adult patients who are newly diagnosed and are transplant eligible, DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib + thalidomide + dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® (daratumumab) in combination with bortezomib + thalidomide + dexamethasone.† DARZALEX FASPRO® is a ready-to-use, single-use vial, which includes a fixed dose and no weight-based calculations.1,2
First dose of the every-2-week dosing schedule is given at Week 9.
First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT.
*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.
†The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.
ARRs=administration-related reactions; ASCT=autologous stem cell transplant; DVTd=DARZALEX FASPRO® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d).